The outlook for patients with systemic lupus erythe matosus (SLE) improved from a 4year survival rate of ~50% in 1950 to a 15year survival rate of ~85% by 2013 (ref.
, is often substantial. An analysis of patients with lupus nephritis (potentially the most harmful disease manifestation) indicated that there had not been a major improvement in outcome in the 30 years to 2011 (ref. 5 ), suggesting that conventional drugs are unlikely to produce any further clinically important beneficial effects in these patients. Hopes had been high that, as with patients with other auto immune rheumatic diseases, those with SLE would bene fit from biologic therapies. However, biologic therapy for the treatment of SLE has been relatively unsuccessful and several biologic agents have failed to meet their primary end points in large scale clinical trials 6, 7 . Thus, physicians treating patients with SLE cur rently cannot choose between several highly successful approved biologic drugs when conventional therapies fail, as is the case for those treating patients with rheu matoid arthritis (RA), psoriatic arthritis (PsA) or anky losing spondylitis 8 . Hence, a clear unmet need exists for targeted biologic therapies, particularly for aspects of dis ease such as lupus nephritis that have a limited number of proven therapies.
In this Review, we consider the current use of biologic therapies to treat patients with SLE and provide some discussion about why previous trials have failed. We also outline several potential new therapies, indicating the pathways that each approach seeks to block. Many therapeutic targets are currently under investigation, and several ongoing clinical trials for SLE have been discussed elsewhere 7 so in this Review, we focus only on those approaches that we consider to be particularly encouraging.
Current use of biologic therapy
In SLE, evidence exists of a general breakdown in both B cell and T cell tolerance, and a number of aspects of B cell biology have been implicated in its pathogen esis 9 . Perhaps the most obvious pathogenic function of B cells in SLE is the production of autoantibodies that target self antigens such as DNA and extractable nuclear antigens. The contribution of B cells to disease initiation and perpetuation in SLE is complex, but it is probable that they help to prime autoreactive T cells, function as antigen presenting cells (APCs) and are a rich source of the cytokines involved in immune dysregulation in SLE 9 . Not surprisingly, many of the therapeutic agents that have been trialled in SLE target B cell pathways 10 . The approaches of these therapeutic agents vary, from targeting B cell selective cell surface molecules (such New therapies for systemic lupus erythematosus -past imperfect, future tense as CD22 or CD20), to inhibiting B cell survival by tar geting cytokines and signalling molecules (such as B cell activating factor (BAFF), IL6, IL17 and IL21), to interfering with B cell antigen presentation by tar geting co stimulatory molecules (such as CD40-CD40 ligand (CD40L) interactions and inducible T cell co sti mulator (ICOS)-ICOS ligand (ICOSL) interac tions). Many of these therapies, including rituximab (an anti CD20 monoclonal antibody (mAb)), epratuzumab (an anti CD22 mAb), abatacept (which stops APCs from interacting with T cells via CD80 and CD86) and tabalumab (an anti BAFF mAb), have not shown a statis tically significant benefit in clinical trials for SLE 11, 12 . However, despite the disappointing results of these (mostly) biologic therapies in clinical trials, not all of the approaches attempted in the past few years have failed completely.
Rituximab and belimumab (an anti BAFF mAb) are the biologic drugs most commonly used to treat SLE in clinical practice. The results of a large number of open label studies of rituximab 11 and the encouraging data from national registries 12, 13 were sufficient for both the ACR 14 and EULAR 15 to recommend rituximab as a treatment for lupus nephritis and for the National Health Service England to sanction its use in difficult totreat patients 16 . For example, in the Lupus Clinic at University College Hospital, London, UK, ~170 patients have been treated with rituximab since 2000 owing to the ineffi cacy of treatment or adverse events following immuno suppression with steroids, azathioprine, mycophenolate mofetil (MMF) or cyclophosphamide (D.A.I., unpub lished observations). Importantly, although rituximab is regarded as being generally effective, its use is associ ated with hypogammaglobulinaemia 17 (which causes an increased risk of infection), and allergy like responses (ranging from a mild cutaneous rash with flushing and pruritus to symptomatic bronchospasm with dysphonia, hypoxia and wheeze) were reported at one centre in 16% of patients treated with rituximab 18, 19 . Following successful clinical trials 20, 21 , belimumab was approved by the FDA in 2012 for use in the USA in patients with SLE and by the National Institute of Clinical Excellence in 2016 for use in the UK in patients with SLE who have active skin and joint disease. Belimumab thus became the first drug to be approved by the FDA for the treatment of SLE in more than 50 years. Encouragingly, a 2018 trial 22 of intravenous belimumab that included 677 patients from China, Japan and South Korea reported a response rate (using the SLE Responder Index (SRI)4 end point) of 53.8% in the belimumab treated group versus 40.1% in those given placebo in addition to standard ofcare treatment. However, this trial 22 excluded patients who had renal disease or central nervous system (CNS) disease. The efficacy and safety of a subcutaneous form of belimumab has also been reported. In a study of 839 patients with SLE, 556 of whom were given belimumab and 280 of whom were given placebo, 61.4% of those taking belimumab met the primary end point of achieving an SRI4 response compared with 48.4% of those taking placebo 23 . Although limited by regulatory bodies and cost, 'real life' data on belimumab use are also emerging. For example, the results of a study from Italy 24 of 188 patients with SLE treated with belimumab who were followed up for a mean of 17.5 months have been reassuring in terms of both efficacy and safety. In this population, the most common disease manifestations that required beli mumab to be started were polyarthritis and skin rashes 24 .
The results of a trial of belimumab in patients with renal disease 25 are still awaited, and more detailed knowledge of the effectiveness of belimumab in SLE manifestations, such as pleuropericarditis, gastrointestinal disease and CNS disease, is also desired.
Despite the clinical practice and, in the case of beli mumab, clinical trial evidence supporting the use of belimumab and rituximab, they are not panaceas, and a proportion of patients remain whose disease is not con trolled by existing B cell targeting strategies. Thus, there remains a 'gap in the market' for successful and relatively adverse effectfree biologic therapies to treat SLE.
Challenges for SLE clinical trials

Assessment of disease activity
Assessing disease activity in SLE can be challenging, not least because it is essential to distinguish clinical features resulting from disease activity from those resulting from concomitant diseases or damage. Several disease activity assessment systems have been developed and validated 26 . The best known disease activity measures are proba bly the SLE Disease Activity Index 2000 (SLEDAI2K) and the British Isles Lupus Assessment Group (BILAG) 2004 disease activity index. The SLEDAI2K provides a simple comprehensive score that is easy to calculate but that does not distinguish features of clinical activity that are only partly improved from those that have not changed 26 . This index also misses out some important clinical features of SLE, including gastrointestinal dis ease, ophthalmic disease and haemolytic anaemia. By contrast, the BILAG2004 disease activity index is more comprehensive and is able to distinguish between dif ferent disease states, but takes longer to complete when the disease is active 26 . A BILAG A or B score refers to new severe (A) or moderate (B) disease activity within a particular domain that typically leads to a change in therapy.
Several composite end points have also been deve l oped, such as the SRI and the BILAG based Composite Lupus Assessment (BICLA), both of which include components of the BILAG2004 disease activity index and the SLEDAI2K. Both the SRI and the BICLA aim 26 . SLE is a complicated disease, and the majority of pharmaceutical companies perform two kinds of trials: renal and non renal. Those that focus on lupus nephri tis have the advantage of hard end points, such as the measurement of protein tocreatinine ratios, serum crea tinine concentrations and glomerular filtration rates, which are not dependent on subjective interpretation, as is the case with non renal SLE. As discussed elsewhere 26 , the use of composite end points, such as the SRI and the BICLA, in addition to the Physicians Global Assessment (PGA) is demanding for clinicians, and whether or not such assessments are better performed without con sideration of medication changes is an ongoing debate. Ideally, clinicians who participate in international clini cal trials should receive formal training in the use of these disease activity measures and be assessed to ensure that they understand the important principles behind these measures. The addition of an independent review panel (separate from the assessors at individual centres and central monitors) to review the data from different centres on a regular basis throughout the trial should also be encouraged. Such an addition makes it easier to highlight individual centres and clinicians whose disease activity assessment results differ substantially from those of other centres and individuals, and to therefore correct any problems during the trial.
Adverse outcomes
Given the failures of many trials, it is encouraging that pharmaceutical companies are still willing to 'engage' with SLE. As with many new forms of therapy, biologic drugs used to treat patients with SLE are monitored very closely for adverse events, including infection, allergic responses, malignancies and deaths (Table 1) . In parti cular, the risk of infection has been a concern in patients with SLE. For example, atacicept (which blocks BAFF and a proliferation inducing ligand (APRIL)) was first used in a flare prevention study 27 . In this study, patients with active SLE (defined by the presence of one or more BILAG A or B scores) were initially treated with gluco corticoids that were sharply tapered once the active disease had been brought under control and were then treated with either a high (150 mg) or low (75 mg) dose of atacicept or placebo. The aims of this study were to look for the time to first flare and the number of flares in the 1year follow up period 27 . However, the safety committee became concerned after two deaths caused by infection in the high dose group, which was sub sequently suspended. Despite this setback, atacicept continued to be developed for SLE and, reassuringly, a trial of 300 patients with active SLE reported no deaths due to atacicept and a serious infection rate of 7% in the placebo group, 8% in the 75 mg atacicept group and 1% in the 150 mg atacicept group 28 . Additionally, a trial of ocrelizumab 29 (an anti CD20 mAb) was termi nated early owing to an increase in the infection rate when combined with MMF; hence, toxicity in patients on background immunosuppressive therapy is an important concern. In the design of future trials, due consideration should be given to the potential for back ground immuno suppressive therapies to increase the risk of adverse events (particularly infections) when used in combi nation with the study drug, and thought should be given to how to minimize background therapy where possible.
Glucocorticoid use
The use of glucocorticoids and other immunosuppres sive drugs in therapeutic trials in the past 10 years seems to have been liberal. In effect, the consequence has been to raise the bar so high that it has become almost impossible for the test drug to really show its merits. For example, two trials of tabalumab, each involving ~1,100 patients, came to different conclusions regard ing the efficacy of the drug, because in one trial 30 the primary end point was not met, whereas in the second study it was 31 . The critical difference between the trials was that, in the first trial 30 , a stipulation was included that any alteration in the steroid dose implied a failure of the drug. On reflection, this stipulation meant that, in patients whose disease had improved while taking tabalumab and whose dose of steroids was subsequently reduced, tabalumab was deemed to have failed. Despite setbacks such as these, detailed post hoc analyses of some trials have revealed encouraging results even when the primary outcomes were not achieved. Clear report ing of concomitant glucocorticoid use and the consid eration of necessary deviations from pre defined dosing NATure revIewS | RhEuMATOlOgy strategies in the final statistical analysis need to be taken into account in the design of future trials.
Promising new therapeutic approaches
The history of SLE therapeutics is littered with agents that seemed promising in preclinical or early phase clinical studies but then failed in late phase trials. Although some of the challenges surrounding trial design will have contributed to these failures, the issues involved are complex, and preclinical success does not guarantee success in clinical practice. Likewise, suc cess in a phase II trial does not guarantee success in a phase III trial. The complexity and heterogeneity of the underlying immune dysregulation in SLE probably also contributes to the failure of trials, and targeting particular cytokines or cell specific pathways within defined patient subgroups will probably be beneficial in the future. figure 1 shows the targets of interventions aimed at immune cells thought to be involved in the pathogene sis of SLE. Accurately predicting which (if any) of these approaches might ultimately prove to be successful is extremely difficult and, for several therapies, trial results are still awaited (Table 2) . Given the complex nature of the aetiopathogenesis of SLE, more than one approach will probably be required. Nonetheless, it is hoped that one or more of the agents discussed below will prove successful for patients with SLE.
Targeting B cells
Anti-CD20 antibodies. The high rate of allergy like responses 19 to rituximab in patients with SLE seems to be related, at least in part, to the fact that rituximab is not fully humanized. A number of alternative, fully human ized, anti CD20 mAbs are becoming available. Two types of anti CD20 mAbs (known as type I and type II) have been identified according to various functional properties 32 (Table 3) .
Ocrelizumab has been studied in two clinical trials in patients with SLE. BEGIN, a phase III study 33 in patients with non renal SLE, was terminated early when the spon sor decided not to pursue this indication. BELONG, a phase III study in patients with lupus nephritis who were treated with ocrelizumab and either cyclophosphamide or MMF was terminated early owing to a high serious infection rate in patients receiving ocrelizumab and MMF 34 . An assessment of the 32week data from this trial revealed renal response rates of 63% and 51% in the ocrelizumab and placebo groups, respectively, and an apparent benefit for those patients receiving addi tional cyclophosphamide 34 . Another fully humanized anti CD20 mAb, obinutuzumab, induced better B cell cytotoxicity than rituximab in patients with RA or SLE 35 . An ongoing phase II trial that is due to last for 1 year aims to investigate the efficacy and safety of this drug in lupus nephritis, with complete renal response as the primary outcome 36 . Although it is unlikely that all of the new anti CD20 agents will reach the market, ofatumumab (an IgG1) 37 has been approved for the treatment of chronic lymphocytic leukaemia, and has also been used to treat autoimmune haemolytic anaemia and immune mediated thrombocytopenia, and lupus nephritis 38 in a small num ber of patients. These agents could have a particular use in patients for whom rituximab has shown efficacy, but allergy like responses have led to its discontinuation.
Combination rituximab and belimumab therapy.
The combination of B cell depletion with rituximab and inhi bition of B cell survival with belimumab is based on the premise that the production of BAFF following B cell depletion might facilitate the maturation of autoreac tive B cells 39 . Several groups have reported preliminary data from small studies that outline the efficacy of such a strategy. The largest of these studies, the CALIBRATE trial, assessed the effect of rituximab with one pulse of cyclophosphamide followed by monthly intravenous belimumab infusions beginning at 4 weeks (n = 21) compared with rituximab and cyclophosphamide alone (n = 22) in patients with active lupus nephritis 40 .
No significant difference in renal response was noted between the groups, although the addition of belimumab did lead to a delay in B cell repopulation without an increase in hypogammaglobulinaemia 40 . The results of the SYNBIOSE study, an open label proof ofconcept study using a similar infusion protocol without the additional cyclophosphamide, have also been reported 41 .
Clinical improvement was noted in a cohort of previ ously refractory patients who had improved SLEDAI scores at week 24 (renal responses were noted in 11 out of 16 patients) 41 , and the results of phase III studies are awaited. In this study 41 , clinical improvement was also mirrored by a reduction in autoantibodies, including anti doublestranded DNA (dsDNA) antibodies, as well as a reduction in neutrophil extracellular trap formation, a process implicated in SLE pathogenesis. A multi centre, double blind, placebo controlled phase III trial, BEAT Lupus, investigating the safety and efficacy of starting belimumab 4-8 weeks after rituximab has completed enrolling patients 42 . Given the conflicting evidence to date, further clarity is needed about the usefulness of combination strategies such as this in treating SLE.
Anti-CD19 antibodies.
A novel humanized anti CD19 antibody called obexelimab (XmAb5871) that has been engineered to have an increased affinity for Fcγ receptor IIB (FcγRIIb) has been used to treat SLE in a phase II NATure revIewS | RhEuMATOlOgy study of 104 patients with moderate tosevere disease 43 . Low disease activity was first achieved by a short course of disease suppressing intramuscular steroids, after which background immunosuppression was stopped, and those with the required disease activity improve ment were randomly allocated 1:1 to XmAb5871 or placebo. Patients were followed up until day 225, and the preliminary results showed that disease activity levels were maintained with no 'loss of improvement' (defined as an increase in SLEDAI of >4 or a new BILAG A or B score (indicating a substantial increase in disease activity)) in 42% of patients treated with XmAb5871 compared with 23% of patients treated with placebo 43 . Given the clinical success of other B cell targeting strat egies, the results of phase III studies of this agent are awaited with interest.
Targeting BTK. Tyrosine protein kinase BTK is expressed by many immune cells, including macro phages, monocytes and B cells, and regulates signalling downstream of the B cell receptor, Fc receptors and, possibly, Toll like receptors 44 . The loss of BTK activity ameliorated lupus like disease in mice 45 , whereas over expression of BTK in cells from mice with lupus like disease caused an increase in anti dsDNA antibody pro duction 46 . A number of BTK inhibitors have been devel oped, including ibrutinib and GDC0853. Ibrutinib is an irreversible tyrosine kinase selective inhibitor that binds to BTK and causes increased B cell apoptosis. A preclinical trial in a mouse model of lupus nephritis 47 showed that ibrutinib treatment reduced the amount of some autoantibodies, including anti nucleosome anti bodies and anti histone antibodies, but not anti dsDNA antibodies, and improved renal disease. GDC0853 (ref. 48 ) is currently being used in an ongoing phase II trial of SLE that aims to assess the efficacy and safety of this therapy in patients with a SLEDAI score of >6 (ref.
49 ). As with many other agents, confirmation that strong preclinical evidence can translate into clinical success is awaited.
Targeting CD40-CD40L interactions. Interest in CD40-CD40L interactions in the pathogenesis of SLE and the potential to therapeutically target this interac tion has been reignited in the past few years. CD40L is a member of the TNF superfamily that engages with its receptor CD40 on B cells, leading to B cell differentia tion, isotype switching and the formation of germinal centres 50 . Owing to their centrality in the induction of a robust immune response, CD40-CD40L interactions are thought to be an important mechanism in the deve l opment of autoimmunity. In SLE, both CD4 + T cells and CD8 + T cells overexpress CD40L during active disease, and CD40L is also aberrantly expressed by monocytes and B cells from patients with SLE 51 . Moreover, trans genic mice that ectopically express CD40L on B cells develop lupus like disease 52 . The results of preclinical studies suggest that inhibition of the CD40-CD40L pathway might help to ameliorate lupus like disease. Specifically, lupus prone NZB/W mice had delayed onset or prevention of proteinuria, improved survival and less severe renal disease when treated with an anti CD40L mAb before the onset of symptoms 53 . Unfortunately, initial clinical studies of anti CD40L mAbs were not promising. Ruplizumab, a humanized anti CD40L antibody, produced a partial therapeutic response in patients with lupus nephritis in an early phase, open label study 54 ; however, an increased inci dence in thrombosis in patients receiving ruplizumab led to the early termination of this study. Another human ized anti CD40L mAb, toralizumab, was also used in a phase II study in patients with SLE but produced no statis tically significant improvements in disease 55 . Similarly, further development of this agent was stopped owing to increased thrombosis in trials of toralizumab in patients with Crohn's disease 56 . The thromboembolic effects of ruplizumab and toralizumab transpired to be mediated by the Fc por tions of these antibodies, resulting in the formation of immune complexes that caused platelet aggregation and activation 57 . Dapirolizumab pegol, a polyethylene glycol conjugated anti CD40L Fab fragment, has been designed to circumvent these issues and showed no evi dence of prothrombotic effects in preclinical studies. This therapeutic agent was evaluated in a 32week phase I study 58 of 24 patients with SLE that was pri marily designed to explore the safety, tolerability and pharmacokinetics of the repeated intravenous dosing regimen. The results of this study revealed potential improvements in disease activity in patients who had high baseline disease activity scores, although the study was not powered to address this question. Treatment with dapirolizumab pegol resulted in an SRI4 response in 41.7% of patients with SLE, compared with 14.3% of patients in the placebo group 58 . A higher incidence of non serious infection was noted in the dapirolizumab pegol group than in the placebo group, but there was no increase in serious infection and, notably, no evidence . The initial results of a phase II study 59 have been announced in a press release 60 . Few data have been provided, but the primary end point of establishing a dose response with P ≤ 0.055 at week 24 was not met (P = 0.06), although "strong evidence of histological activity and improvement in the majority of clinical endpoints" was reported in patients given dapirolizumab pegol 60 . The full results of this study and a decision as to whether further trials of this agent will be pursued in SLE are still awaited.
Targeting ICOS-ICOSL interactions. ICOS is a T cell specific molecule that is expressed on the cell surface upon T cell activation and interacts with ICOSL, which is a constitutively expressed molecule on APCs, including B cells 61 . Functionally, ICOS is a co stimulatory molecule similar to CD28 that causes T cell activation and con tributes to B cell differentiation 61 . Increased numbers of ICOS expressing T cells and B cells with reduced expres sion of ICOSL are found in the blood of patients with SLE 62 , indicating that T cell-B cell interactions might have just taken place. The results of a phase II trial to assess the safety profile and toler ability of AMG 557, an anti ICOSL mAb, in patients with mild SLE was reported in 2016 (ref.
63
). AMG 557 had an acceptable safety pro file and the anticipated pharmacokinetic profile 63 . Further trials are awaited to assess the clinical efficacy of antiICOSL antibody therapy in SLE.
Targeting immune complexes. The Fc region of IgG is recognized by FcγRs, transmembrane proteins that are expressed on B cells and dendritic cells 64 . The binding of immune complexes to FcγRs triggers intracellular sig nalling pathways, which ultimately causes an immune response. FcγRIIB is an inhibitory receptor, unlike most other FcγR molecules, which tend to be activatory, and is an important regulator of activated B cells. Notably, patients with SLE have a reduced expression of FcγRIIB 65 . FcγRIIB has a limited degree of polymorphism in humans and is not immunogenic. An extracellular ver sion of human FcγRIIB has been developed (known as SM101), which acts as a decoy receptor by binding to immune complexes and thereby preventing FcγR mediated signalling. In an encouraging 24week phase IIa trial, 51 patients with SLE were randomly allocated to receive weekly doses of SM101 or placebo for 4 weeks 66 . SLEDAI, BILAG and PGA scores were recorded, as well as global response and renal parameter measure ments, even though this was primarily a safety study. No serious unexpected adverse events occurred and the SRI4 response was doubled in the SM101 group com pared with the placebo group; results were particularly encouraging in patients with lupus nephritis 66 . Given the encouraging results of the phase II study, it will be interesting to see if this is a viable agent in phase III studies, particularly for the treatment of renal disease.
Rigerimod. Rigerimod is a therapeutic agent that is theo retically appealing for the treatment of SLE. Rigerimod is a 21amino acid linear peptide derived from the small nuclear ribonucleoprotein U170K that has the addition of phosphorylation at Ser140 (ref.
67
). Rigerimod causes the depletion of autoreactive T cells via apoptosis with out affecting the ability of T cells and B cells to respond to antigens, making it immunomodulatory rather than immunosuppressive, although the mechanism of action is not completely understood. In lupus prone MRL/lpr mice, rigerimod treatment reduced disease activity (particularly vasculitis, protein excretion and skin dis ease) and anti dsDNA antibody production 68 . Phase II clinical studies of rigerimod have shown some promise. In a 2012 phase IIb study, 149 patients with active SLE (SLEDAI2K score of ≥6, patients with an A score in any BILAG domain excluded at screening) were randomly allocated to receive placebo or subcutaneous rigeri mod every 2 or 4 weeks in addition to standard ofcare therapy 69 . 53% of patients treated with monthly rigeri mod attained an SRI4 response at week 12 compared with 36% of those treated with placebo (P = 0.048) 69 . A post hoc analysis of a subpopulation of patients who had a clinical SLEDAI score of ≥6 at baseline revealed an even greater magnitude of response between the monthly rigerimod group and the placebo group (P < 0.025) 69 . Similar to belimumab, it seems that the greatest clinical benefit occurs in patients with predominant articular and cutaneous disease. This study 69 also included an analysis at 24 weeks, but the beneficial effects of riger imod at the end of this additional 12week treatment free period were less evident. However, the initial results of a phase III study of rigerimod 70 (reported in a press release) 71 showed that, although rigerimod demon strated a good safety profile and a superior response rate to placebo (68.8% versus 59%) in the 153 patients who completed the trial (the difference was greatest among anti dsDNA antibody positive patients), the difference was not statistically significant. The equivocal and non significant response to rigerimod in phase III trials means that the usefulness of rigerimod as a treatment for SLE is unclear. Interestingly, an open label extension of the phase III study was announced in 2018 and is yet to be reported 72 .
Targeting the interferon pathway
Many patients with SLE have an increased expression of genes regulated by type I interferons in peripheral blood cells (known as the interferon gene signature), the pro ducts of which have diverse effects on the innate immune system and the adaptive immune system 73 . Evidence also exists to support a genetic association between SLE and type I interferon associated genes 74 , and a high preva lence of 'drug induced SLE' occurs in patients receiving therapeutic IFNα 75 . Together, these findings have pro moted a strong interest in developing agents targeting type I interferons for use in SLE. Importantly, although most studies to date have focused on the inhibition of IFNα, the type I interferon family comprises 13 sub types of IFNα, as well as IFNβ, IFNε, IFNκ and IFNω, which mediate their biological effects by binding to the common type I interferon receptor (IFNAR) 76 . Contrary to expectations, there have been conflict ing results from studies of type I interferon pathway inhibition. Rontalizumab and sifalimumab are mAbs that directly inhibit IFNα. In a phase II study of patients with SLE, rontalizumab did not meet the primary or secondary end points, although the results surprisingly suggested a benefit for patients with a low baseline inter feron gene signature in their peripheral blood cells 77 . By contrast, sifalimumab met its primary end point in a phase II study of patients with SLE, and the results suggested a benefit for patients with a high interferon signature; however, the clinical benefits were modest compared with placebo (56% and 58% of patients in the two sifalimumab groups achieved an SRI4 response compared with 45% of patients in the placebo group) 78 . The fully human IgG1κ antibody anifrolumab antag onizes IFNAR, thereby downregulating the effects of all type I interferons. In a 2017 phase IIb study 79 , in addition to standard ofcare therapy, intravenous anifrolumab was superior to placebo in patients with moderate to severe SLE treated over a 48week period. The primary end point of this study was the percentage of patients attaining an SRI4 response at 24 weeks in addition to a sustained reduction of oral glucocorticoids from weeks 12-24, which was achieved in 34% of patients receiv ing 300 mg/month anifrolumab compared with 17.6% receiving placebo 79 . The advantage over placebo was less pronounced for patients receiving 1,000 mg/month anifrolumab (28.8% of patients achieved an SRI4 response), suggesting a possible plateau effect 79 . Similar to sifalimumab, in this study 79 , the greatest benefit was noted in patients with a high baseline interferon gene signature; 75% of patients had a high baseline inter feron gene signature, and it was the response rate in this subpopulation that caused the difference between the treatment and placebo groups in the study, suggest ing that selecting this cohort of patients for treatment with type I interferon inhibition could be beneficial. Similar to other studies of type I interferon inhibitors, an increase in viral infections (particularly herpes zoster infections) was noted in the anifrolumab groups 79 , con sistent with the mechanism of action of these agents. However, despite the optimism generated by the results of the phase II trial 79 , a phase III study (TULIP1) 80 of 463 patients with SLE who have mucocutaneous and/or musculoskeletal disease did not meet its end point of reducing disease activity (SRI4 response) 81 . A further phase II study specifically addressing the efficacy of anifrolumab in patients with active proliferative lupus nephritis is ongoing 82 . Indirect inhibition of the type 1 interferon pathway by means of an IFNα kinoid vaccine has also been studied in patients with SLE. This vaccine comprises IFNα2b cou pled to a carrier protein, which together induce native, polyclonal neutralizing anti IFNα antibodies 83 . This vaccine substantially reduced the interferon gene signa ture in patients with SLE in a phase I study 84 . A larger phase IIb study is ongoing to address the efficacy, safety and immunogenicity of this agent in SLE 85 .
Targeting the JAK-STAT pathway
The Janus kinase (JAK)-signal transducer and acti vator of transcription (STAT) pathway is the primary signalling mechanism downstream of type 1 and type 2 cytokine receptors. Polymorphisms in genes encoding JAK and STAT proteins increase susceptibility to SLE 86 , and inhibition of the JAK-STAT pathway is already used to treat many autoimmune diseases (including RA and PsA) 87 . In a preclinical study, tofacitinib (a JAK1 and JAK3 inhibitor) reduced both kidney disease and the concen tration of pathogenic autoantibodies in lupus prone mice 88 . The results of a phase II trial of baricitinib 89 (an oral JAK1 and JAK2 inhibitor) in 314 patients with SLE who have active cutaneous disease or musculo skeletal activity were reported in 2018. 67% of patients receiving 4 mg/day baricitinib achieved a SLEDAI2K response at 24 weeks, which was significantly more than those receiving placebo (53%; P = 0.04) 89 . Treatment with 4 mg/day baricitinib also reduced the proportion of patients with 'worst joint pain' compared with pla cebo and improved PGA and low disease activity scores; however, the 2 mg/day dose of baricitinib did not show any benefit compared with placebo 89 . The phase III BRAVE I 90 and BRAVE II 91 studies, which aim to assess the effects of baricitinib in patients with SLE, are cur rently recruiting. Whether JAK inhibitors are more effi cacious for non organthreatening disease (in particular, active joint disease or cutaneous disease) is unclear, and the results of these studies are keenly awaited.
Targeting IL-12 and IL-23
Blockade of IL12 and IL23 is already used to success fully treat psoriasis and PsA
92
, and evidence suggests that these cytokines might be involved in some aspects of SLE pathogenesis 93 . The results of a phase II, placebo controlled trial of ustekinumab 94 (an antibody against IL12 and IL23) in 102 seropositive patients with SLE were reported in 2018. All patients had a SLEDAI2K score of ≥6 and/or two BILAG B scores and were receiv ing standard ofcare therapy to which was added either a single infusion of intravenous ustekinumab followed by subcutaneous ustekinumab every 8 weeks, or a sin gle infusion of intravenous placebo followed by subcu taneous placebo every 8 weeks 94 . 60% of patients treated with ustekinumab achieved the primary end point of an SRI4 response at 6 months compared with 31% of the placebo treated group (P = 0.0046) 94 , which was a very encouraging result. The risk of a new flare (one BILAG A score or two new BILAG B scores) was sig nificantly lower in the ustekinumab treated group than in the placebo treated group (P = 0.0078) 94 . Particularly encouraging results were also observed for patients with active cutaneous disease and articular involvement at baseline, and the safety profile of ustekinumab in this study was similar to the safety profile in studies for other indications. Patients are currently being recruited for a phase III study to assess the efficacy of ustekinumab as a therapy for SLE 95 , the results of which are required to determine its true potential in the clinic.
Conclusions
The development and implementation of new thera pies for SLE has lagged behind that of other rheumatic diseases, but many new molecular pathways and tar gets have been studied in the past two decades, some of which show promise for SLE. Given the problems encountered in previous clinical trials, most notably those of rituximab, it is clear that the design of trials for www.nature.com/nrrheum SLE needs to be revisited to decide the most objective indicator of response for this complex condition and to enable a clear distinction between the active treatment and, often quite substantial, background immunosup pression. In this Review, we have highlighted a number of promising targets and pathways but, increasingly, success in phase II trials has not been followed by the achievement of primary end points in phase III trials. In general, clinical trials for SLE should aim to minimize background therapy (particularly glucocorticoids), use individual organ or system outcome measures rather than relying solely on composite measures and have stringent requirements for the selection of trial sites. Such measures would help to maximize the chances of the therapies in development being successful. Although there is room for some optimism, the challenges of bringing successful new biologic therapies into everyday clinical practice for SLE remain daunting.
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